Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Standard Biotools (LAB) EBITDA Margin (2016 - 2025)

Standard Biotools (LAB) has disclosed EBITDA Margin for 16 consecutive years, with 3226.05% as the latest value for Q3 2025.

  • On a quarterly basis, EBITDA Margin rose 174365.0% to 3226.05% in Q3 2025 year-over-year; TTM through Sep 2025 was 93.93%, a 7424.0% increase, with the full-year FY2024 number at 100.46%, down 2843.0% from a year prior.
  • EBITDA Margin was 3226.05% for Q3 2025 at Standard Biotools, up from 90.51% in the prior quarter.
  • In the past five years, EBITDA Margin ranged from a high of 3226.05% in Q3 2025 to a low of 224.61% in Q2 2024.
  • A 5-year average of 163.7% and a median of 75.87% in 2023 define the central range for EBITDA Margin.
  • Peak YoY movement for EBITDA Margin: plummeted -16154bps in 2024, then surged 174365bps in 2025.
  • Standard Biotools' EBITDA Margin stood at 29.42% in 2021, then crashed by -166bps to 78.13% in 2022, then increased by 3bps to 75.87% in 2023, then increased by 10bps to 68.24% in 2024, then surged by 4828bps to 3226.05% in 2025.
  • Per Business Quant, the three most recent readings for LAB's EBITDA Margin are 3226.05% (Q3 2025), 90.51% (Q2 2025), and 80.82% (Q1 2025).